NASDAQ: MRVI Q4 and Year-end 2024 Financial Results 01 Welcome Deb Hart, Head of Investor Relations 02 10-K Update, Financial Results & Guidance Kevin Herde, Chief Financial Officer 03 Business Highlights & Strategy Trey Martin, Chief Executive Officer 04 Q&A Session Trey Martin, Chief Executive Officer Kevin Herde, Chief Financial Officer © 2025 Maravai LifeSciences 2 Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains, and our officers and representatives may, from ...

Maravai LifeSciences (MRVI) Q4 2024 Earnings Call March 20, 2025 05:00 PM ET Company Participants Deb Hart - Head of Investor RelationsKevin Herde - Executive VP & CFOTrey Martin - CEODoug Schenkel - Managing DirectorRicki Levitus - Equity Research Associate - Life Sciences Tools & DiagnosticsDan Arias - Managing DirectorBrandon Couillard - Managing Director Conference Call Participants Matt Stanton - AnalystMatt Larew - Research Analyst - HealthcareTejas Savant - Executive Director & Senior Healthcare Equi ...

NEW YORK, March 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI).Shareholders who purchased shares of MRVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission-form/?id=137092&fr ...

Core Viewpoint - Maravai LifeSciences Holdings, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and inadequate internal controls over financial reporting [1][3]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Nelson v. Maravai LifeSciences Holdings, Inc., and it allows purchasers of Maravai securities from August 7, 2024, to February 24, 2025, to seek lead plaintiff status by May 5, 2025 [1][5]. - Allegations include that Maravai lacked adequate internal controls over financial reporting, inaccurately recognized revenue during fiscal 2024, and overstated goodwill [3][4]. - On February 25, 2025, Maravai announced a postponement of its fiscal 2024 earnings release due to issues related to revenue recognition and a potential non-cash impairment charge, leading to a nearly 22% drop in stock price [4][3]. Group 2: Company Background - Maravai LifeSciences is a provider of biologics that support clinical research [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud cases, having recovered $6.6 billion for investors in such cases [6].

LOS ANGELES, March 19, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Maravai LifeSciences Holdings, Inc. ("Maravai" or "the Company") (NASDAQ: MRVI) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between August 7, 2024 and February 24, 2025, inclusive (the "C ...

Core Viewpoint - A class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for allegedly misrepresenting its financial condition and revenue recognition practices during a specified period [1][2]. Group 1: Allegations - The lawsuit alleges that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2] - It is claimed that the company inaccurately recognized revenue on certain transactions during fiscal 2024 [2] - The complaint also states that Maravai's goodwill was overstated, leading to materially misleading statements about the company's business and prospects [2] Group 2: Stock Impact - Following the revelation of an error in revenue recognition and a material weakness in internal controls, Maravai's stock price fell over 21% to close at $3.14 per share on February 25, 2025 [3] Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers with the court by May 5, 2025 [4] - Shareholders can remain absent class members if they choose not to participate in the case [4] Group 4: Company Background - Maravai LifeSciences is a life sciences company that provides products for drug therapy development, diagnostics, novel vaccines, and research support on human diseases globally [1]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) | Delaware | 85-2786970 | | --- | --- | | (State or other juris ...

Earnings Release Delay - Maravai LifeSciences Holdings, Inc. announced a delay in its earnings release and call originally scheduled for February 25, 2025, due to the need for additional time to complete its financial close process[5]. - The company intends to file a Form 12b-25 for late filing with the SEC on or before March 4, 2025, and plans to submit its annual report on Form 10-K for the fiscal year ended December 31, 2024, by March 18, 2025[5]. Preliminary Revenue Results - Preliminary revenue results for the year ended December 31, 2024, were included in the February 2025 Press Release, although specific figures were not disclosed in the provided content[6].

Schedules Conference Call for Thursday, March 20, 2025SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2024, together with other business updates. The company also expects to file its Annual Report on Form 10-K for the year ended December 31, 2024, with the Securities ...

NEW YORK, March 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences" or the "Company") (NASDAQ: MRVI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Maravai LifeSciences investors who were adversely affected by alleged securities fraud between August 7, 2024 and February 24, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zl ...